Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Down 22.4% in March

Definium Therapeutics, Inc. (NASDAQ:DFTX) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 15,008,738 shares, a decline of 22.4% from the February 26th total of 19,343,010 shares. Currently, 15.4% of the company’s shares are sold short. Based on an average daily trading volume, of 1,813,075 shares, the short-interest ratio is currently 8.3 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. JonesTrading began coverage on shares of Definium Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. HC Wainwright increased their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Jefferies Financial Group initiated coverage on shares of Definium Therapeutics in a report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $35.70.

Definium Therapeutics Stock Up 8.0%

Shares of Definium Therapeutics stock traded up $1.40 on Tuesday, reaching $18.90. The stock had a trading volume of 2,282,789 shares, compared to its average volume of 1,823,396. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.88 billion, a P/E ratio of -8.87 and a beta of 2.56. The company has a 50 day moving average price of $17.41 and a 200 day moving average price of $14.11. Definium Therapeutics has a 1 year low of $4.70 and a 1 year high of $19.67.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DFTX. BIT Capital GmbH acquired a new position in Definium Therapeutics in the third quarter valued at approximately $26,000. Fifth Third Bancorp increased its holdings in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after purchasing an additional 3,300 shares in the last quarter. Sound Income Strategies LLC acquired a new position in shares of Definium Therapeutics in the 3rd quarter valued at $46,000. Russell Investments Group Ltd. boosted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.